Pembrolizumab and Cabozantinib in Recurrent Metastatic Head and Neck Squamous Cell Carcinoma (RMHNSCC): 2-year Long Term Survival Update with Biomarker AnalysisNabil F. Saba, Christine H. Chung, Ashley McCook et al.|International Journal of Radiation Oncology*Biology*Physics|2024Cited by 0